Comparison 3. Betamimetic versus placebo/no treatment (maternal outcomes).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Side effects sufficient to stop therapy	2	141	Risk Ratio (M‐H, Fixed, 95% CI)	2.71 [0.11, 64.79]
1.1 Ritodrine versus placebo	1	95	Risk Ratio (M‐H, Fixed, 95% CI)	2.71 [0.11, 64.79]
1.2 Terbutaline versus placebo	1	46	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Tachycardia	4	414	Risk Ratio (M‐H, Fixed, 95% CI)	2.13 [1.52, 2.98]
2.1 Ritodrine versus placebo	3	368	Risk Ratio (M‐H, Fixed, 95% CI)	2.41 [1.59, 3.66]
2.2 Terbutaline versus placebo	1	46	Risk Ratio (M‐H, Fixed, 95% CI)	1.5 [0.86, 2.61]
3 Tachypnoea	2	260	Risk Ratio (M‐H, Fixed, 95% CI)	3.52 [1.20, 10.33]
3.1 Ritodrine versus placebo	1	120	Risk Ratio (M‐H, Fixed, 95% CI)	4.21 [0.95, 18.67]
3.2 Terbutaline versus placebo	1	140	Risk Ratio (M‐H, Fixed, 95% CI)	2.83 [0.59, 13.56]
4 Hypotension	2	166	Risk Ratio (M‐H, Fixed, 95% CI)	1.89 [1.13, 3.19]
4.1 Ritodrine versus placebo	1	120	Risk Ratio (M‐H, Fixed, 95% CI)	2.81 [0.30, 26.22]
4.2 Terbutaline versus placebo	1	46	Risk Ratio (M‐H, Fixed, 95% CI)	1.8 [1.08, 3.01]
5 Nausea	2	186	Risk Ratio (M‐H, Fixed, 95% CI)	0.95 [0.43, 2.13]
5.1 Terbutaline versus placebo	2	186	Risk Ratio (M‐H, Fixed, 95% CI)	0.95 [0.43, 2.13]
6 Vomiting	2	235	Risk Ratio (M‐H, Fixed, 95% CI)	1.28 [0.44, 3.70]
6.1 Ritodrine versus placebo	1	95	Risk Ratio (M‐H, Fixed, 95% CI)	2.71 [0.11, 64.79]
6.2 Terbutaline versus placebo	1	140	Risk Ratio (M‐H, Fixed, 95% CI)	1.13 [0.36, 3.54]
7 Palpitations	1	140	Risk Ratio (M‐H, Fixed, 95% CI)	5.67 [1.32, 24.40]
7.1 Terbutaline versus placebo	1	140	Risk Ratio (M‐H, Fixed, 95% CI)	5.67 [1.32, 24.40]
8 Headache	1	95	Risk Ratio (M‐H, Fixed, 95% CI)	2.71 [0.11, 64.79]
8.1 Ritodrine versus placebo/no treatment	1	95	Risk Ratio (M‐H, Fixed, 95% CI)	2.71 [0.11, 64.79]